{"id":36546,"topic":"peptides","source":"TradingView","title":"The Precision Peptide Company Inc. Receives 20,000-Unit Production Run of BPC-157 Transdermal Patches - TradingView","url":"https://www.tradingview.com/news/tmx_newsfile:5beaf1e7a094b:0-the-precision-peptide-company-inc-receives-20-000-unit-production-run-of-bpc-157-transdermal-patches/","url_hash":"9beeded197664f7cf5bdd5b910dceb40080663f1","author":"","summary":"<a href=\"https://news.google.com/rss/articles/CBMi9gFBVV95cUxQNHJqWEVnUUFhRHhsaWtpaDNpSGt4bnZENExkRU9uRDJPTmtGVWVmSmY1VTdJZ3NpUHVlNEVWY1lnY2N3MHIzT1hhbElGaEtDVzRfVHNYWUxEMDl1N0tGLWZKbTZ0UnpOQmNuNXdDRERPTjZ2YkpyUndCUzVnMVh6UHdnQzhqT2pkQ2FaN2hHRG5jUWlaRVV3cGx5YXRvVjBqb3haVnBhZ2g5N2ZtMXpBQVpoaHhxVHJoYUliZm5tTVllZU5zT1YwNTFhTGdHMDlmRkNkQ3BZWlAtalRBY1A5MDZodEljWDhVdXF2dnFqQ0NFMHY3VWc?oc=5\" target=\"_blank\">The Precision Peptide Company Inc. Receives 20,000-Unit Production Run of BPC-157 Transdermal Patches</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">TradingView</font>","content":"The Precision Peptide Company Inc. Receives 20,000-Unit Production Run of BPC-157 Transdermal Patches\nHighlights\n- Received full production run of approximately 20,000 BPC-157 transdermal patches, the Company's lead product candidate\n- Patches are manufactured and independently tested in the United States\n- Marks the Company's transition from testing to commercialization\n- Each patch delivers 2 mg of BPC-157, consistent with the 95.5% purity and 2.02 mg dose\nVancouver, British Columbia--(Newsfile Corp. - July 14, 2026) - The Precision Peptide Company BPC (OTCQB: PNGAF) (the \"Company\" or \"BPC\"), a publicly traded wellness company focused on advanced peptide formulations and delivery systems, today announces that it has received its production run of approximately 20,000 units of its BPC-157 transdermal patch (the \"Patch\"), the Company's lead product candidate. The arrival of this commercial inventory follows the Company's previously announced order (previously announced here) and represents a key step in the Company's transition from testing and formulation validation to commercialization.\nThe Patch is proudly manufactured in the United States and was independently tested by a U.S. analytical laboratory. Each Patch is formulated to deliver 2 mg of BPC-157, consistent with the third-party test results reported in the Company's previous news release, which confirmed 95.5% chromatographic purity, exceeding the ≥95% threshold that is widely recognized across the peptide industry as the analytical benchmark for high-purity grade peptide products, and a quantified dose of 2.02 mg of BPC-157 per patch.\nWith commercial inventory now in hand, the Company is positioned to proceed toward the initial commercial release of the Patch through The Precision Peptide Company website.\nPratap Sandhu, CEO of The Precision Peptide Company, commented:\n\"We are proud that our patches are made and tested right here in the U.S. That reflects the standard we've set for ourselves and for our customers. We ordered 20,000 units and they've now arrived, which moves us into fulfillment as we prepare to begin selling through our website.\"\nAbout The Precision Peptide Company\nThe Precision Peptide Company BPC (OTCQB: PNGAF) is a publicly traded wellness company building a next-generation platform for high-quality peptide formulations. By combining scientific formulation and innovative delivery technologies, the Company creates products at the intersection of biotechnology and scalable consumer wellness. Products are manufactured in an approved U.S. facility and distributed across North America.\nFor more information, visit: www.precisionpeptidecompany.com\nCompany Contact\nPratap Sandhu CEO, Corporate Secretary and Director\npratap@precisionpeptidecompany.com\n+1 (604) 765-8069\nCautionary Note Regarding Forward-Looking Information","image_url":"https://static.tradingview.com/static/images/logo-preview.png","lang":"en","published_at":"2026-07-14T11:00:00+00:00","fetched_at":"2026-07-14T16:15:10+00:00","status":"read","starred":0,"extract_state":"ok","summary_auto":"Receives 20,000-Unit Production Run of BPC-157 Transdermal Patches\nHighlights\n- Received full production run of approximately 20,000 BPC-157 transdermal patches, the Company's lead product candidate\n- Patches are manufactured and independently tested in the United States\n- Marks the Company's transition from testing to commercialization\n- Each patch delivers 2 mg of BPC-157, consistent with the 95.5% purity and 2.02 mg dose\nVancouver, British Columbia--(Newsfile Corp. - July 14, 2026) - The Precision Peptide Company BPC (OTCQB: PNGAF) (the \"Company\" or \"BPC\"), a publicly traded wellness company focused on advanced peptide formulations and delivery systems, today announces that it has received its production run of approximately 20,000 units of its BPC-157 transdermal patch (the \"Patch\"), the Company's lead product candidate.","cluster_id":1709475,"extract_retries":0,"extract_error":null,"contract_version":"news_item.v1","format_contract_version":"news_item_formats.v1","dedup_url":"https://www.tradingview.com/news/tmx_newsfile:5beaf1e7a094b:0-the-precision-peptide-company-inc-receives-20-000-unit-production-run-of-bpc-157-transdermal-patches/","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 2840 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":2840,"summary_length":836,"usable_text_length":2840,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":2840,"summary_length":836}},"news_item":{"id":36546,"canonical_url":"https://www.tradingview.com/news/tmx_newsfile:5beaf1e7a094b:0-the-precision-peptide-company-inc-receives-20-000-unit-production-run-of-bpc-157-transdermal-patches/","source_url":"https://www.tradingview.com/news/tmx_newsfile:5beaf1e7a094b:0-the-precision-peptide-company-inc-receives-20-000-unit-production-run-of-bpc-157-transdermal-patches/","title":"The Precision Peptide Company Inc. Receives 20,000-Unit Production Run of BPC-157 Transdermal Patches - TradingView","source_name":"TradingView","author":null,"published_at":"2026-07-14T11:00:00+00:00","locale":"en","topic":"peptides","tags":[],"rss_summary":"<a href=\"https://news.google.com/rss/articles/CBMi9gFBVV95cUxQNHJqWEVnUUFhRHhsaWtpaDNpSGt4bnZENExkRU9uRDJPTmtGVWVmSmY1VTdJZ3NpUHVlNEVWY1lnY2N3MHIzT1hhbElGaEtDVzRfVHNYWUxEMDl1N0tGLWZKbTZ0UnpOQmNuNXdDRERPTjZ2YkpyUndCUzVnMVh6UHdnQzhqT2pkQ2FaN2hHRG5jUWlaRVV3cGx5YXRvVjBqb3haVnBhZ2g5N2ZtMXpBQVpoaHhxVHJoYUliZm5tTVllZU5zT1YwNTFhTGdHMDlmRkNkQ3BZWlAtalRBY1A5MDZodEljWDhVdXF2dnFqQ0NFMHY3VWc?oc=5\" target=\"_blank\">The Precision Peptide Company Inc. Receives 20,000-Unit Production Run of BPC-157 Transdermal Patches</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">TradingView</font>","full_text":"The Precision Peptide Company Inc. Receives 20,000-Unit Production Run of BPC-157 Transdermal Patches\nHighlights\n- Received full production run of approximately 20,000 BPC-157 transdermal patches, the Company's lead product candidate\n- Patches are manufactured and independently tested in the United States\n- Marks the Company's transition from testing to commercialization\n- Each patch delivers 2 mg of BPC-157, consistent with the 95.5% purity and 2.02 mg dose\nVancouver, British Columbia--(Newsfile Corp. - July 14, 2026) - The Precision Peptide Company BPC (OTCQB: PNGAF) (the \"Company\" or \"BPC\"), a publicly traded wellness company focused on advanced peptide formulations and delivery systems, today announces that it has received its production run of approximately 20,000 units of its BPC-157 transdermal patch (the \"Patch\"), the Company's lead product candidate. The arrival of this commercial inventory follows the Company's previously announced order (previously announced here) and represents a key step in the Company's transition from testing and formulation validation to commercialization.\nThe Patch is proudly manufactured in the United States and was independently tested by a U.S. analytical laboratory. Each Patch is formulated to deliver 2 mg of BPC-157, consistent with the third-party test results reported in the Company's previous news release, which confirmed 95.5% chromatographic purity, exceeding the ≥95% threshold that is widely recognized across the peptide industry as the analytical benchmark for high-purity grade peptide products, and a quantified dose of 2.02 mg of BPC-157 per patch.\nWith commercial inventory now in hand, the Company is positioned to proceed toward the initial commercial release of the Patch through The Precision Peptide Company website.\nPratap Sandhu, CEO of The Precision Peptide Company, commented:\n\"We are proud that our patches are made and tested right here in the U.S. That reflects the standard we've set for ourselves and for our customers. We ordered 20,000 units and they've now arrived, which moves us into fulfillment as we prepare to begin selling through our website.\"\nAbout The Precision Peptide Company\nThe Precision Peptide Company BPC (OTCQB: PNGAF) is a publicly traded wellness company building a next-generation platform for high-quality peptide formulations. By combining scientific formulation and innovative delivery technologies, the Company creates products at the intersection of biotechnology and scalable consumer wellness. Products are manufactured in an approved U.S. facility and distributed across North America.\nFor more information, visit: www.precisionpeptidecompany.com\nCompany Contact\nPratap Sandhu CEO, Corporate Secretary and Director\npratap@precisionpeptidecompany.com\n+1 (604) 765-8069\nCautionary Note Regarding Forward-Looking Information","excerpt":"Receives 20,000-Unit Production Run of BPC-157 Transdermal Patches\nHighlights\n- Received full production run of approximately 20,000 BPC-157 transdermal patches, the Company's lead product candidate\n- Patches are manufactured and independently tested in the United States\n- Marks the Company's transition from testing to commercialization\n- Each patch delivers 2 mg of BPC-157, consistent with the 95.5% purity and 2.02 mg dose\nVancouver, British Columbia--(Newsfile Corp. - July 14, 2026) - The Precision Peptide Company BPC (OTCQB: PNGAF) (the \"Company\" or \"BPC\"), a publicly traded wellness company focused on advanced peptide formulations and delivery systems, today announces that it has received its production run of approximately 20,000 units of its BPC-157 transdermal patch (the \"Patch\"), the Company's lead product candidate.","extraction":{"state":"ok","confidence":0.9,"error":null,"explanation":"High confidence: full text extraction produced 2840 characters.","diagnostics_url":"/api/diagnose?url=https%3A//www.tradingview.com/news/tmx_newsfile%3A5beaf1e7a094b%3A0-the-precision-peptide-company-inc-receives-20-000-unit-production-run-of-bpc-157-transdermal-patches/","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 2840 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":2840,"summary_length":836,"usable_text_length":2840,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":2840,"summary_length":836}}},"display_formats":["compact","card","full","digest_section","json"]},"daily_stack_record":{"title":"The Precision Peptide Company Inc. Receives 20,000-Unit Production Run of BPC-157 Transdermal Patches - TradingView","url":"https://www.tradingview.com/news/tmx_newsfile:5beaf1e7a094b:0-the-precision-peptide-company-inc-receives-20-000-unit-production-run-of-bpc-157-transdermal-patches/","summary":"Receives 20,000-Unit Production Run of BPC-157 Transdermal Patches\nHighlights\n- Received full production run of approximately 20,000 BPC-157 transdermal patches, the Company's lead product candidate\n- Patches are manufactured and independently tested in the United States\n- Marks the Company's transition from testing to commercialization\n- Each patch delivers 2 mg of BPC-157, consistent with the 95.5% purity and 2.02 mg dose\nVancouver, British Columbia--(Newsfile Corp. - July 14, 2026) - The Precision Peptide Company BPC (OTCQB: PNGAF) (the \"Company\" or \"BPC\"), a publicly traded wellness company focused on advanced peptide formulations and delivery systems, today announces that it has received its production run of approximately 20,000 units of its BPC-157 transdermal patch (the \"Patch\"), the Company's lead product candidate.","source":"TradingView","date":"2026-07-14T11:00:00+00:00","content":"The Precision Peptide Company Inc. Receives 20,000-Unit Production Run of BPC-157 Transdermal Patches\nHighlights\n- Received full production run of approximately 20,000 BPC-157 transdermal patches, the Company's lead product candidate\n- Patches are manufactured and independently tested in the United States\n- Marks the Company's transition from testing to commercialization\n- Each patch delivers 2 mg of BPC-157, consistent with the 95.5% purity and 2.02 mg dose\nVancouver, British Columbia--(Newsfile Corp. - July 14, 2026) - The Precision Peptide Company BPC (OTCQB: PNGAF) (the \"Company\" or \"BPC\"), a publicly traded wellness company focused on advanced peptide formulations and delivery systems, today announces that it has received its production run of approximately 20,000 units of its BPC-157 transdermal patch (the \"Patch\"), the Company's lead product candidate. The arrival of this commercial inventory follows the Company's previously announced order (previously announced here) and represents a key step in the Company's transition from testing and formulation validation to commercialization.\nThe Patch is proudly manufactured in the United States and was independently tested by a U.S. analytical laboratory. Each Patch is formulated to deliver 2 mg of BPC-157, consistent with the third-party test results reported in the Company's previous news release, which confirmed 95.5% chromatographic purity, exceeding the ≥95% threshold that is widely recognized across the peptide industry as the analytical benchmark for high-purity grade peptide products, and a quantified dose of 2.02 mg of BPC-157 per patch.\nWith commercial inventory now in hand, the Company is positioned to proceed toward the initial commercial release of the Patch through The Precision Peptide Company website.\nPratap Sandhu, CEO of The Precision Peptide Company, commented:\n\"We are proud that our patches are made and tested right here in the U.S. That reflects the standard we've set for ourselves and for our customers. We ordered 20,000 units and they've now arrived, which moves us into fulfillment as we prepare to begin selling through our website.\"\nAbout The Precision Peptide Company\nThe Precision Peptide Company BPC (OTCQB: PNGAF) is a publicly traded wellness company building a next-generation platform for high-quality peptide formulations. By combining scientific formulation and innovative delivery technologies, the Company creates products at the intersection of biotechnology and scalable consumer wellness. Products are manufactured in an approved U.S. facility and distributed across North America.\nFor more information, visit: www.precisionpeptidecompany.com\nCompany Contact\nPratap Sandhu CEO, Corporate Secretary and Director\npratap@precisionpeptidecompany.com\n+1 (604) 765-8069\nCautionary Note Regarding Forward-Looking Information","confidence":0.9,"diagnostics_url":"/api/diagnose?url=https%3A//www.tradingview.com/news/tmx_newsfile%3A5beaf1e7a094b%3A0-the-precision-peptide-company-inc-receives-20-000-unit-production-run-of-bpc-157-transdermal-patches/","quality_bucket":"high","failure_kind":"none","retryable":false,"quality_reason":"High confidence: full text extraction produced 2840 characters.","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 2840 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":2840,"summary_length":836,"usable_text_length":2840,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":2840,"summary_length":836}},"tags":[]},"fallback_formats":["markdown","json","html"],"actions":{"read":"/item/36546","export_markdown":"/api/items/36546/export?format=markdown","export_json":"/api/items/36546/export?format=json","diagnose":"/api/diagnose?url=https%3A//www.tradingview.com/news/tmx_newsfile%3A5beaf1e7a094b%3A0-the-precision-peptide-company-inc-receives-20-000-unit-production-run-of-bpc-157-transdermal-patches/"},"formats":{"full":{"id":36546,"title":"The Precision Peptide Company Inc. Receives 20,000-Unit Production Run of BPC-157 Transdermal Patches - TradingView","url":"https://www.tradingview.com/news/tmx_newsfile:5beaf1e7a094b:0-the-precision-peptide-company-inc-receives-20-000-unit-production-run-of-bpc-157-transdermal-patches/","source":"TradingView","author":null,"published_at":"2026-07-14T11:00:00+00:00","locale":"en","topic":"peptides","tags":[],"excerpt":"Receives 20,000-Unit Production Run of BPC-157 Transdermal Patches\nHighlights\n- Received full production run of approximately 20,000 BPC-157 transdermal patches, the Company's lead product candidate\n- Patches are manufactured and independently tested in the United States\n- Marks the Company's transition from testing to commercialization\n- Each patch delivers 2 mg of BPC-157, consistent with the 95.5% purity and 2.02 mg dose\nVancouver, British Columbia--(Newsfile Corp. - July 14, 2026) - The Precision Peptide Company BPC (OTCQB: PNGAF) (the \"Company\" or \"BPC\"), a publicly traded wellness company focused on advanced peptide formulations and delivery systems, today announces that it has received its production run of approximately 20,000 units of its BPC-157 transdermal patch (the \"Patch\"), the Company's lead product candidate.","full_text":"The Precision Peptide Company Inc. Receives 20,000-Unit Production Run of BPC-157 Transdermal Patches\nHighlights\n- Received full production run of approximately 20,000 BPC-157 transdermal patches, the Company's lead product candidate\n- Patches are manufactured and independently tested in the United States\n- Marks the Company's transition from testing to commercialization\n- Each patch delivers 2 mg of BPC-157, consistent with the 95.5% purity and 2.02 mg dose\nVancouver, British Columbia--(Newsfile Corp. - July 14, 2026) - The Precision Peptide Company BPC (OTCQB: PNGAF) (the \"Company\" or \"BPC\"), a publicly traded wellness company focused on advanced peptide formulations and delivery systems, today announces that it has received its production run of approximately 20,000 units of its BPC-157 transdermal patch (the \"Patch\"), the Company's lead product candidate. The arrival of this commercial inventory follows the Company's previously announced order (previously announced here) and represents a key step in the Company's transition from testing and formulation validation to commercialization.\nThe Patch is proudly manufactured in the United States and was independently tested by a U.S. analytical laboratory. Each Patch is formulated to deliver 2 mg of BPC-157, consistent with the third-party test results reported in the Company's previous news release, which confirmed 95.5% chromatographic purity, exceeding the ≥95% threshold that is widely recognized across the peptide industry as the analytical benchmark for high-purity grade peptide products, and a quantified dose of 2.02 mg of BPC-157 per patch.\nWith commercial inventory now in hand, the Company is positioned to proceed toward the initial commercial release of the Patch through The Precision Peptide Company website.\nPratap Sandhu, CEO of The Precision Peptide Company, commented:\n\"We are proud that our patches are made and tested right here in the U.S. That reflects the standard we've set for ourselves and for our customers. We ordered 20,000 units and they've now arrived, which moves us into fulfillment as we prepare to begin selling through our website.\"\nAbout The Precision Peptide Company\nThe Precision Peptide Company BPC (OTCQB: PNGAF) is a publicly traded wellness company building a next-generation platform for high-quality peptide formulations. By combining scientific formulation and innovative delivery technologies, the Company creates products at the intersection of biotechnology and scalable consumer wellness. Products are manufactured in an approved U.S. facility and distributed across North America.\nFor more information, visit: www.precisionpeptidecompany.com\nCompany Contact\nPratap Sandhu CEO, Corporate Secretary and Director\npratap@precisionpeptidecompany.com\n+1 (604) 765-8069\nCautionary Note Regarding Forward-Looking Information","reading_time_min":2,"extraction":{"state":"ok","confidence":0.9,"error":null,"explanation":"High confidence: full text extraction produced 2840 characters.","diagnostics_url":"/api/diagnose?url=https%3A//www.tradingview.com/news/tmx_newsfile%3A5beaf1e7a094b%3A0-the-precision-peptide-company-inc-receives-20-000-unit-production-run-of-bpc-157-transdermal-patches/","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 2840 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":2840,"summary_length":836,"usable_text_length":2840,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":2840,"summary_length":836}}},"quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 2840 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":2840,"summary_length":836,"usable_text_length":2840,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":2840,"summary_length":836}},"actions":{"read":"/item/36546","export_markdown":"/api/items/36546/export?format=markdown","export_json":"/api/items/36546/export?format=json","diagnose":"/api/diagnose?url=https%3A//www.tradingview.com/news/tmx_newsfile%3A5beaf1e7a094b%3A0-the-precision-peptide-company-inc-receives-20-000-unit-production-run-of-bpc-157-transdermal-patches/"}},"digest":{"id":36546,"title":"The Precision Peptide Company Inc. Receives 20,000-Unit Production Run of BPC-157 Transdermal Patches - TradingView","url":"https://www.tradingview.com/news/tmx_newsfile:5beaf1e7a094b:0-the-precision-peptide-company-inc-receives-20-000-unit-production-run-of-bpc-157-transdermal-patches/","source":"TradingView","topic":"peptides","published_at":"2026-07-14T11:00:00+00:00","excerpt":"Receives 20,000-Unit Production Run of BPC-157 Transdermal Patches Highlights - Received full production run of approximately 20,000 BPC-157 transdermal patches, the Company's lead product candidate - Patches are manufactured and independently tested in the United States - Marks…","quality_bucket":"high","quality_reason":"High confidence: full text extraction produced 2840 characters.","reading_time_min":2,"cluster_id":1709475},"card":{"display_title":"The Precision Peptide Company Inc. Receives 20,000-Unit Production Run of BPC-157 Transdermal Patches - TradingView","subtitle":"TradingView · 2026-07-14","summary":"Receives 20,000-Unit Production Run of BPC-157 Transdermal Patches Highlights - Received full production run of approximately 20,000 BPC-157 transdermal patches, the Company's lead product candidate - Patches are…","badges":["quality:high"],"links":{"read":"/item/36546","original":"https://www.tradingview.com/news/tmx_newsfile:5beaf1e7a094b:0-the-precision-peptide-company-inc-receives-20-000-unit-production-run-of-bpc-157-transdermal-patches/","diagnose":"/api/diagnose?url=https%3A//www.tradingview.com/news/tmx_newsfile%3A5beaf1e7a094b%3A0-the-precision-peptide-company-inc-receives-20-000-unit-production-run-of-bpc-157-transdermal-patches/"},"quality_warning":null},"export":{"title":"The Precision Peptide Company Inc. Receives 20,000-Unit Production Run of BPC-157 Transdermal Patches - TradingView","url":"https://www.tradingview.com/news/tmx_newsfile:5beaf1e7a094b:0-the-precision-peptide-company-inc-receives-20-000-unit-production-run-of-bpc-157-transdermal-patches/","summary":"Receives 20,000-Unit Production Run of BPC-157 Transdermal Patches\nHighlights\n- Received full production run of approximately 20,000 BPC-157 transdermal patches, the Company's lead product candidate\n- Patches are manufactured and independently tested in the United States\n- Marks the Company's transition from testing to commercialization\n- Each patch delivers 2 mg of BPC-157, consistent with the 95.5% purity and 2.02 mg dose\nVancouver, British Columbia--(Newsfile Corp. - July 14, 2026) - The Precision Peptide Company BPC (OTCQB: PNGAF) (the \"Company\" or \"BPC\"), a publicly traded wellness company focused on advanced peptide formulations and delivery systems, today announces that it has received its production run of approximately 20,000 units of its BPC-157 transdermal patch (the \"Patch\"), the Company's lead product candidate.","source":"TradingView","date":"2026-07-14T11:00:00+00:00","content":"The Precision Peptide Company Inc. Receives 20,000-Unit Production Run of BPC-157 Transdermal Patches\nHighlights\n- Received full production run of approximately 20,000 BPC-157 transdermal patches, the Company's lead product candidate\n- Patches are manufactured and independently tested in the United States\n- Marks the Company's transition from testing to commercialization\n- Each patch delivers 2 mg of BPC-157, consistent with the 95.5% purity and 2.02 mg dose\nVancouver, British Columbia--(Newsfile Corp. - July 14, 2026) - The Precision Peptide Company BPC (OTCQB: PNGAF) (the \"Company\" or \"BPC\"), a publicly traded wellness company focused on advanced peptide formulations and delivery systems, today announces that it has received its production run of approximately 20,000 units of its BPC-157 transdermal patch (the \"Patch\"), the Company's lead product candidate. The arrival of this commercial inventory follows the Company's previously announced order (previously announced here) and represents a key step in the Company's transition from testing and formulation validation to commercialization.\nThe Patch is proudly manufactured in the United States and was independently tested by a U.S. analytical laboratory. Each Patch is formulated to deliver 2 mg of BPC-157, consistent with the third-party test results reported in the Company's previous news release, which confirmed 95.5% chromatographic purity, exceeding the ≥95% threshold that is widely recognized across the peptide industry as the analytical benchmark for high-purity grade peptide products, and a quantified dose of 2.02 mg of BPC-157 per patch.\nWith commercial inventory now in hand, the Company is positioned to proceed toward the initial commercial release of the Patch through The Precision Peptide Company website.\nPratap Sandhu, CEO of The Precision Peptide Company, commented:\n\"We are proud that our patches are made and tested right here in the U.S. That reflects the standard we've set for ourselves and for our customers. We ordered 20,000 units and they've now arrived, which moves us into fulfillment as we prepare to begin selling through our website.\"\nAbout The Precision Peptide Company\nThe Precision Peptide Company BPC (OTCQB: PNGAF) is a publicly traded wellness company building a next-generation platform for high-quality peptide formulations. By combining scientific formulation and innovative delivery technologies, the Company creates products at the intersection of biotechnology and scalable consumer wellness. Products are manufactured in an approved U.S. facility and distributed across North America.\nFor more information, visit: www.precisionpeptidecompany.com\nCompany Contact\nPratap Sandhu CEO, Corporate Secretary and Director\npratap@precisionpeptidecompany.com\n+1 (604) 765-8069\nCautionary Note Regarding Forward-Looking Information","confidence":0.9,"diagnostics_url":"/api/diagnose?url=https%3A//www.tradingview.com/news/tmx_newsfile%3A5beaf1e7a094b%3A0-the-precision-peptide-company-inc-receives-20-000-unit-production-run-of-bpc-157-transdermal-patches/","quality_bucket":"high","failure_kind":"none","retryable":false,"quality_reason":"High confidence: full text extraction produced 2840 characters.","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 2840 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":2840,"summary_length":836,"usable_text_length":2840,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":2840,"summary_length":836}},"tags":[],"format_contract_version":"news_item_formats.v1"}}}